|
Biotech Co.* |
Pharma Co. |
Type/Product Area |
Terms/Details (Date) |
|
AEterna |
Nippon Kayaku Co. Ltd. (Japan) |
Nippon Kayaku got rights in Japan to ozarelix, a hormone-releasing hormone antagonist |
The deal covers oncology indications; AEterna gets an up-front payment along with potential milestone payments and low-double-digit royalties (8/3) |
|
Affinergy |
Synthes GmbH (Switzerland) |
Development and license deal focused on orthopedic products from Synthes |
Affinergy will use its site-specific biological delivery technology in the deal, terms of which were not disclosed (9/11) |
|
Affinergy |
DuPont Pharmaceuticals BioSurfaces business |
Affinergy will help in R&D of a new line of bio-based products for Dupont's |
Affinergy will use its site-specific biological delivery technology in the deal, terms of which were not disclosed (8/3) |
|
Anthera |
Eli Lilly and Co. and Shionogi & Co. Ltd.(Japan) |
Anthera got rights outside Japan to a platform of phospholipase A2 inhibitors |
The anti-inflammatory agents were part of a collaboration between Lilly and Shionogi; terms of the deal were not disclosed (9/6) |
|
Argenta |
AstraZeneca plc (UK) |
Argenta will provide medicinal chemistry services to support drug discovery at AstraZeneca |
Terms of the deal were not disclosed; they do, however, provide options to expand the collaboration (7/25) |
|
Artisan |
Asahi Kasei Pharma Corp. (Japan) |
Artisan got rights outside Asia to the thrombomodulin agent ART-123 |
The product has been in Phase III trials; terms of the deal were not disclosed (9/6) |
|
Auriga |
Degussa AG (Germany) |
Deal to develop a new formulation targeting chronic gastrointestinal diseases using Degussa's delivery technology |
The technology will be used for delivery of an oral, controlled- release corticosteroid formulation from Auriga; terms were not disclosed (8/22) |
|
Axordia Ltd.* |
Lombard Medical Technologies plc (UK) |
Deal to develop a regenerative stent for treating coronary artery disease |
They will use Axordia's stem cell- derived endovascular cells with Lombard's coating material in the 2.5-year project; terms were not disclosed (8/3) |
|
BioDelivery |
Meda AB (Sweden) |
Meda got rights in Europe to BDSI's BEMA Fentanyl product |
BDSI gets $2.5M up front, up to $7.5M in milestone payments, and would get double-digit royalties on sales of the product, which is being developed to treat pain (8/3) |
|
BrainCells |
Mitsubishi Pharma Corp. (Japan) |
BrainCells licensed a central nervous system compound that Mitsubishi previously had in development |
BrainCells plans to reposition the compound, BCI-540, and develop it for CNS diseases; terms of the deal were not disclosed (8/10) |
|
Caliper Life |
Schering-Plough Corp. |
Xenogen Biosciences will characterize targets arising from Schering-Plough research |
Xenogen was acquired by Caliper a week earlier; it will use its Serial Phenotyping Compression Technology in the deal, terms of which were not disclosed (8/17) |
|
Cell |
Novartis AG (Switzerland) |
Deal to develop and market CTI's Xyotax, which is in Phase III trials in cancer indications; Novartis also got an option to develop the cancer agent pixantrone |
Novartis is making a $15M equity investment in CTI, which also could get up to $270M in regulatory and sales milestones for Xyotax; CTI also has a U.S. co-detailing option; for pixantrone, CTI could get $7.5M up front and and up to $104M in milestone payments (9/18) |
|
CepTor Corp. |
Ferring International Center SA (Switzerland) |
CepTor got rights to acquire recombinant human copper zinc superoxide dismutase (SOD) for prevention of chronic respiratory morbidity in premature newborns |
Pending agreement with the FDA on Phase IIb trials, CepTor would give Ferring an option payment; Ferring also could get a royalty-free license to the product for infertility indications (9/15) |
|
Cerep SA |
Servier |
Cerep will use its screening and chemistry capabilities in lead- identification programs for Servier |
Cerep also will use its BioPrint platform to characterize drug candidates; the collaboration includes three different deals; terms were not disclosed (8/7) |
|
ChemoCentryx |
GlaxoSmithKline |
Multitarget deal to develop and market drugs for treating inflammatory disorders; the deal includes ChemoCentryx's Traficet-EN, which is in clinical trials for Crohn's disease |
ChemoCentryx gets $63.5M up front in cash and an equity investment; it also will get research funding, and could get up to $1.5B in milestones across six product options on the four targets; it also would get double-digit royalties on any resulting sales (8/24) |
|
Clinuvel |
Genepharm Australasia Ltd. (Australia) |
Genepharm is acquiring Clinuvel's EpiPharm line of dermatology products |
Clinuvel is receiving A$1M ($0.75M) for the products and related assets (9/12) |
|
Clontech |
Bayer HealthCare AG (Germany) |
Clontech got worldwide rights to sell its Ready-To-Glow systems for use in research and high-throughput screening |
The reporter assay kits use a secreted luciferase isolated by Bayer; terms of the deal were not disclosed (7/26) |
|
CogState Ltd. |
H. Lundbeck A/S (Denmark) |
Lundbeck will use CogState's cognitive testing services in a clinical trial |
Terms of the deal were not disclosed (8/23) |
|
Crucell NV |
Novartis AG (Switzerland) |
Deal to apply Crucell's STAR technology in the the production of cell lines |
They also will adapt the procedures to specific parental cell lines; the program will involve different monoclonal antibodies; terms were not disclosed (9/14) |
|
Crucell NV |
UCB SA (Belgium) |
UCB got nonexclusive rights to use STAR technology in the production of monoclonal antibodies |
Crucell is entitled to a license fee, milestone payments and maintenance fees under the five-year research license (9/7) |
|
Dynavax |
AstraZeneca plc (UK) |
Deal to develop TLR-9 agonist- based therapies for treating asthma and chronic obstructive pulmonary disease |
Dynavax gets $10M up front and up to $17M more in research and preclinical milestone payments; it also is eligible to receive $109M more in milestone payments, and royalties on resulting sales (9/6) |
|
Entelos Inc. |
Novartis Pharma AG (Switzerland) |
Entelos will conduct biosimulation research to help in research and development of Novartis drug candidates |
Novarits will provide R&D funding for the effort; further terms were not disclosed (8/22) |
|
Evotec AG |
Olympus Corp. (Japan) |
Olympus acquired Evotec's Single Molecule Detection Technology and corresponding intellectual property |
That part of Evotec's business generated €2.5M ($3.2M) in revenues in 2005; terms of the deal were not disclosed (7/21) |
|
ExonHit |
Allergan Inc. |
They extended deal begun in 2003 to develop drugs for neurodegenerative diseases, pain and ophthalmology indications |
The deal now runs through December 2009; the field of neurodegenerative disease was added; ExonHit gets a payment, and is entitled to increased R&D, milestone and royalty payments (9/19) |
|
ExonHit |
Merck & Co. Inc. |
Merck got research rights to use microarray technology for monitoring RNA splicing events |
Revenues to ExonHit were not expected to exceed $0.15M per year under the non- exclusive deal (9/6) |
|
Galapagos |
AstraZeneca plc (UK) |
Contract under which Galapagos unit BioFocus DPI will provide medicinal chemistry services |
The focus is AstraZeneca discovery pro- grams in the areas of respiratory and inflammatory diseases; the contract value is €0.65M ($0.83M) (8/3) |
|
GeneGo Inc.* |
Applied Biosystems Group |
Collaboration to enhance researchers' ability to study differential gene expression in biological pathways |
As part of the deal, GeneGo integrated the Applied Biosystems Tissue Gene Expression Database into its MetaCore data-mining platform (8/3) |
|
Geospiza Inc.* |
Applied Biosystems Group |
They extended deal to integrate genetic analysis technologies |
Geospiza also is participating in Applied Biosystems' Software Community Program (8/28) |
|
Gilead |
Merck & Co. Inc. |
Deal for the distribution of their Atripla HIV product in developing countries |
Gilead will manufacture and Merck will distribute the product in countries covered by the agreement (8/11) |
|
Gilead |
Three generic manufacturers in India |
Emcure Pharmaceuticals Ltd., Hetero Drugs Ltd. and Strides Arcolab Ltd. got certain rights to the HIV drug Viread |
The companies got rights to produce and distribute generic versions of the drug in 95 low-income countries, including India; terms were not disclosed (8/14) |
|
Graffinity |
Boehringer Ingelheim Pharmaceuticals Inc. (Germany) |
Discovery deal under which Graffinity will generate small- molecule hit series against multiple drug targets |
Terms of the deal were not disclosed (9/7) |
|
GTx Inc. |
Ipsen (France) |
Ipsen got rights in Europe to GTx's Acapodene in all indications except breast cancer; Phase III trials in two prostate cancer indications are ongoing |
GTx gets €23M ($29.41M) up front, and up to €39M ($49.88M) in milestone payments based on the two indications; it also would get a royalty rate from the mid-teens to the mid-twenties (9/7) |
|
Iconix |
Merck KGaA (Germany) |
Services deal under which Iconix will evaluate new drug candidates from Merck |
Iconix will provide in vitro toxicogenomics services; terms of the deal were not disclosed (7/26) |
|
Illumina Inc. |
ReaMetrix Inc. |
Collaboration to co-develop molecular diagnostic panels for a range of disease areas |
ReaMetrix will get nonexclusive rights to resulting products in India; Illumina will retain rights outside of India (7/20) |
|
Immunetrics |
Eli Lilly and Co. |
They extended deal focused on the application of in silico modeling technology to clinical trial design |
The collaboration expands on an earlier project to validate the use of Immunetrics' in silico models of inflammation; terms were not disclosed (8/30) |
|
Immunicon |
AstraZeneca plc (UK) |
Deal to develop methods to identify and quantify certain cell types circulating in blood for use as biomarkers for targeted therapies |
The deal includes two agreements, one covering research and the other laboratory services; the focus is cancer and infectious diseases; terms were not disclosed (8/7) |
|
ImmunoGen |
Sanofi-Aventis U.S. LLC |
Sanofi exercised its option to extend the term of their deal to develop antibody-based anticancer compounds |
ImmunoGen now gets research funding through August 2008; also, it no longer will have to turn over new targets to Sanofi (8/31) |
|
Intercell AG |
Wyeth |
Wyeth got nonexclusive rights to use Intercell's adjuvant IC31 in various infectious disease vaccine programs |
Intercell is eligible to receive up to $77M in up-front, option and milestone payments in the deal, as well as royalties on resulting sales (9/12) |
|
ISTA |
Senju Pharmaceutical Co.Ltd. (Japan) |
ISTA acquired North American rights to an eye-drop formulation of bepotastine, which royalties on any resulting sales; Phase III is being developed to treat allergic conjunctivitis |
ISTA will provide Senju up to $6M in up- front and milestone payments, as well as trials are planned for early 2007 (8/2) |
|
Karo Bio AB |
Wyeth |
They extended collaboration in atherosclerosis for one year, through August 2007 |
The work, focused on targeting the hormone receptor LXR, began in 2001; terms were not disclosed (8/7) |
|
Kinaxo |
Schering AG (Germany) |
Kinaxo will perform selectivity analysis services for small- olecule kinase inhibitors from Schering |
Kinaxo will use its KinaTor technology in the effort; terms of the deal were not disclosed (7/27) |
|
Lentigen |
Dharmacon Inc. (unit of Fisher Biosciences) |
Deal to develop lentiviral expression reagents to deliver short hairpin RNA expression vectors into cells using RNAi mediated gene silencing |
The goal is to create lentiviral reagents for RNAi research; terms of the deal were not disclosed (8/30) |
|
Ligand |
Eisai Co. Ltd. (Japan) |
Eisai is acquiring Ligand's oncology product line and the associated assets |
Ligand is getting $205M for the assets, which include four marketed products (9/7) |
|
Ligand |
King Pharmaceuticals Inc. |
Asset purchase deal under which King acquired Avinza, a marketed extended- release morphine product |
King is paying Ligand $265M and assuming a $48M product-related liability; Ligand also will get royalties on sales (9/7) |
|
MaxCyte Inc.* |
Medinet Co. Ltd. (Japan) |
MaxCyte will provide technology to aid in the development of Medinet's cancer immuno-cell therapy |
MaxCyte will optimize its cell-loading system for the program, and for use in manufacturing at Medinet's cell processing centers; terms were not disclosed (8/17) |
|
Medicure Inc. |
Merck & Co. Inc. |
Merck got first rights on product opportunities outside North America that combine MC-1 with Aggrastat |
The deal was made along with Medicure's acquisition of U.S. rights to the cardiovascular drug Aggrastat from MGI Pharma Inc., which had acquired them from Merck; MC-1 is a drug candidate from Medicure (8/9) |
|
Medivir AB |
Bristol-Myers Squibb Co. |
Worldwide deal to develop MIV-170, a preclinical non- nucleoside reverse transcriptase inhibitor for HIV |
Medivir gets $7.5M up front, and is eligible to receive up to $97M in milestone payments, as well as up to double- digit royalties; it retained rights in Nordic countries (9/13) |
|
Meridian |
Merck KGaA (Germany) |
Collaboration for the development of assays for the clinical market |
Meridian will sell resulting products; terms of the deal were not disclosed (8/14) |
|
Momenta |
Sandoz (unit of Novartis AG; Switzerland) |
Deal to develop four follow-on and generic versions of approved recombinant and complex drugs, including one late-stage compound from Momenta and two from Sandoz |
Sandoz is purchasing $75M in Momenta stock at $15.93 per share, a 30% premium; Momenta also is eligible to receive up to $188M in milestone payments, and would get a share of profits on resulting sales (an equal share for its drug candidate) (7/25) |
|
Nanogen |
Fisher Scientific International Inc. |
They expanded relationship to include an R&D collaboration in molecular diagnostics |
Fisher may provide up to $10M through 2008 for the effort focused on infectious disease and molecular diagnostic tests; Nanogen also will work with Fisher unit Athena Diagnostics to develop in vitro diagnostics based on Athena biomarkers (8/3) |
|
New River |
Shire plc (UK) |
New River exercised its option to co- promote NRP104in the U.S. |
New River will provide 25% of detailing for at least two years; the product, targeting attention deficit hyperactivity disorder, is the subject of a January 2005 deal between the companies (7/25) |
|
NovaCal |
Alcon Inc. |
Alcon got rights to NovaCal's Aganocide compounds to treat infections of the eye, ear and sinus |
NovaCal gets an up-front payment and four years of research funding, as well as potential milestone and royalty payments (9/18) |
|
Odyssey |
Pfizer Inc. |
Deal to use Odyssey's PCA technology to evaluate the selectivity of Pfizer compounds |
Odyssey is entitled to up-front, research and milestone payments in the multiyear deal, which expands an existing relationship (9/5) |
|
Oscient |
Abbott Canada |
Abbott got rights to Factive in Canada, where it is approved for acute bacterial exacer-bations of chronic bronchitis |
Oscient will get a transfer price on product purchases, and is entitled to certain regulatory and sales milestone payments (8/10) |
|
Oscient |
Reliant Pharmaceuticals Inc. |
Oscient acquired U.S. rights to the approved cardiovascular product Antara (fenofibrate) |
The drug is indicated as an adjunct treatment for high blood cholesterol and high triglycerides; Reliant will receive $78M for the product, which generated sales of $35M in the prior 12 months (7/24) |
|
Oxford Gene |
Yamatake Corp. (Japan) |
Yamatake got a license to use OGT's patents on oligonucleotide microarrays |
The deal allows Yamatake to manufacture microarrays, which will be distributed by Sigma-Aldrich Japan KK (8/8) |
|
Pozen Inc. |
AstraZeneca plc (UK) |
Deal to develop and sell fixed-dose combinations of the proton pump inhibitor esomeprazole magnesium with the NSAID naproxen |
Pozen get $40M up front, up to $160M in development and regulatory milestones, and up to $175M in sales milestones; it also would get royalties ranging from the mid-single digits to the mid-teens (8/2) |
|
Procognia |
Teva Pharmaceutical Industries Ltd. (Israel) |
Teva gained exclusive access to glycoanalysis technology for use in the development of two compounds |
Procognia is eligible to receive milestone and royalty payments in the deal; further terms were not disclosed (9/20) |
|
Protein |
UMN Pharma Inc. (Japan) |
UMN got rights in Japan to PSC's recombinant influenza vaccine FluBlOk |
PSC is entitled to a multimillion-dollar up- front payment and double-digit royalties on resulting sales(8/29) |
|
Proteome |
Agilent Technologies Inc. |
They expanded deal to develop solutions for the discovery of diagnostic markers and drug targets by glycomics analysis |
Proteome will provide Agilent with glycomics applications and software development for use with Agilent's mass spectrometer instruments; terms were not disclosed (8/9) |
|
Revotar Bio-pharmaceuticals |
Undisclosed U.S. company |
Deal to develop and market Revotar's Bimosiamose in the field of dermatology |
The product is a synthetic pan-selectin agonist; Revotar gets an up-front fee; a development deal could follow (8/22) |
|
Sapphire |
Novo Nordisk A/S (Denmark) |
Sapphire licensed rights to a selective small-molecule ghrelin mimetic |
Sapphire plans to move the agent into Phase II trials in postoperative ileus; terms of the deal were not disclosed (9/19) |
|
Shanghai |
Centocor Inc. (unit of Johnson & Johnson) |
Collaboration to research inflammatory signaling pathways, for use in drug discovery at Centocor |
Research will focus in the areas of inflammation and oncology; terms of the 1.5-year deal were not disclosed (7/25) |
|
Sirion |
Laboratorios Sophia SA de CV (Mexico) |
Sirion got U.S. rights to a cyclosporine A-based topical solution for ophthalmic uses |
The product, ST-603, is expected to enter clinical testing in 2007; terms of the deal were not disclosed (7/24) |
|
SkyePharma |
Mundipharma International Holdings Ltd. (UK) |
Mundipharma got rights to market Flutiform in Europe and other areas outside North and South America |
SykePharma gets €15M ($19.18M)up front, and up to €70M ($89.52M) in milestone payments; it would get double-digit royalties; the combination product is being developed for chronic obstructive pulmonary disease (9/6) |
|
Stratagene |
Rosetta Inpharmatics LLC (unit of Merck & Co. Inc.) |
Deal to create an automated solution for the isolation of nucleic acids from a variety of clinical samples |
Stratagene would manufacture and commercialize resulting products; terms of the deal were not disclosed (8/14) |
|
Syntaxin Ltd.* |
Allergan Inc. |
Deal to develop clostridial endopeptidase-based compounds |
Syntaxin is entitled to up-front, milestone and royalty payments in the deal, which expanded an existing collaboration (9/4) |
|
Talecris |
Bausch & Lomb |
Bausch & Lomb got exclusive rights to use recombinant Plasmin technology in ophthalmology applications |
Talecris is entitled to milestone and royalty payments in the deal; it is developing the product in non-ocular indications (8/29) |
|
TransTech |
Pfizer Inc. |
Pfizer got rights to TransTech compounds targeting the receptor for advanced glycation end products; the initial focus is Alzheimer's disease |
TransTech is entitled to up-front and near- term milestone payments of $155M, as well as additional milestone payments for other indications; it also will get research funding, and would get royalties on sales (9/18) |
|
Trimeris Inc. |
F. Hoffmann- La Roche Ltd. (Switzerland) |
They extended for two years a deal focused on discovery of next-generation HIV fusion inhibitors |
The deal begun in 2000 now runs through 2008; they are splitting costs equally, and would split any profits (9/7) |
|
Tripos Inc. |
Servier Group (France) |
They extended collaboration focused on identifying drug candidates for obesity |
Tripos Discovery Research Ltd. is providing chemistry services to Servier; Tripos gets research fees and potential preclinical milestone payments (7/31) |
|
Xanthus |
Schering AG (Germany) |
Xanthus got worldwide rights to a group of targeted cancer compounds |
Schering gets an up-front payment, and is eligible to receive milestone and royalty payments; lead compound P2045 has been in Phase I trials in lung cancer (9/6) |
|
Xenon |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Takeda gained a right of first negotiation to certain atherosclerosis discoveries made by Xenon |
Takeda Research Investment Inc. made a $5M equity investment in Xenon; specifics of the deal were not disclosed (9/12) |
|
YM |
Daiichi Pharmaceutical Co. Ltd. (Japan) |
Daiichi got rights in Japan to nimotuzumab (TheraCIM), an anti-EGFR humanized antibody against cancer |
YM subsidiary CimYM BioSciences Inc. gets $14.5 up front, along with potential milestone payments; it also would get payments from sales in Japan (7/31) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange; VSE = Vienna Stock Exchange. | |||
To read more on related topics, click on one of the words below.